Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Prospective, Randomized, Double-Blind, Multi-center, Placebo-Controlled Trial of DaxibotulinumtoxinA for Injection for the Management of Plantar Fasciitis

NCT03825315 is registered in ClinicalTrials.gov with Revance Therapeutics, Inc. as lead sponsor.

NCT NCT03825315
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03825315 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Prospective, Randomized, Double-Blind, Multi-center, Placebo-Controlled Trial of DaxibotulinumtoxinA for Injection for the Management of Plantar Fasciitis
Lead sponsor
Revance Therapeutics, Inc.
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2018
Completion date
June 4, 2020
Enrollment
155 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

plantar fasciitis